Recombinant herpes simplex viruses vaccines and methods
AssigneeArch Development Corporation
InventorBernard Roizman
Life of this patent
Estimating the term…
Abstract
A virus is disclosed which is rendered avirulent by prevention of expression of an active product of a gene which is designated as .gamma..sub.1 34.5, which maps in the inverted repeats flanking the long unique sequence of herpes simplex virus DNA, and which is not essential for viral growth in cell culture. Viruses from which the gene was deleted or which carried stop codons are totally avirulent on intracerebral inoculation of mice.
Claims45
A recombinant herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus genome rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product.
A herpes simplex virus designated R3616 (ATCC VR2280).
A herpes simplex virus designated R4009 (ATCC VR2278).
A vaccine comprising a herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus genome rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier.
A method for immunizing a human host against a herpes simplex virus comprising the step of inoculating said host with an immunity-inducing dose of a vaccine comprising a herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier.
A method for preparing a herpes simplex virus vaccine comprising the steps of:
- preventing transcription of an active product from an ICP34.5 gene in an otherwise substantially intact herpes simplex virus;
- and
- combining said vaccine virus with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.